Beijing Yuanhefa Biotechnology Co., Ltd.

The main purpose of this trial is to expand bone marrow primitive mesenchymal stem cells in vitro to prepare mesenchymal stem cell preparations for clinical use in the treatment of acute myocardial infarction. Due to its innovative technology and theory, it has found a new treatment strategy for many cardiovascular diseases. The treatment scope can also be further expanded to other cardiovascular diseases that require tissue repair or transplantation, especially for the elderly and people with abnormal function of major organs.